Evaluation of a Closed-Loop Control System for Administering Patient-Specific Anesthesia

Numerous efforts have focused on the development of closed-loop systems to control anesthesia using the electrical activity of the brain (EEG) and EEG-based parameters as surrogate measures of anesthetic depth. New systems have been recently developed to considerably improve anesthetic control using model-based, patient-adaptive methods. The purpose of this study is to evaluate the clinical efficacy of a new intelligent software, ReinLoop, in delivering closed-loop, patient-specific hypnosis.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • device: ReinLoop control software for patient-specific induction and maintenance of anesthesia
  • drug: Propofol

Eligibility


Inclusion Criteria:

   1. 18-45 years of age

   2. Body mass index (BMI) lower or equal to 25 m2/kg

   3. Subjects must be able to comprehend spoken and written English

Exclusion Criteria:

   1. Any type of psychiatric, neurological, or neuromuscular disorder

   2. Thyroid disease

   3. History of smoking

   4. Alcohol consumption which exceeds 2 drinks per day and /or drug abuse. Volunteers will
   be asked the question: How many drinks are you drinking on your typical day?

   5. Allergy to study medication (propofol), soy, or egg proteins.

   6. History of drug abuse

   7. Chronic or acute use of opioids, or other medications affecting the CNS

   8. Pregnancy

Ages Eligible for Study

18 Years - 45 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting

Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation,  mobile application development, and pharmaceutical trials.  

Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.